GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats

Diabetes

Volumn 63, Issue 2, 2014, Pages 505-513

  Habegger, Kirk M ^a   Heppner, Kristy M ^a   Amburgy, Sarah E ^a   Ottaway, Nickki ^a   Holland, Jenna ^a   Raver, Christine ^a   Bartley, Erin ^a   Müller, Timo D ^b   Pfluger, Paul T ^b   Berger, Jose ^a   Toure, Mouhamadoul ^a   Benoit, Stephen C ^a   DiMarchi, Richard D ^c   Perez Tilve, Diego ^a   D'Alessio, David A ^a   Seeley, Randy J ^a   Tschöp, Matthias H ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; IMPAIRED GLUCOSE TOLERANCE; LIPID DIET; MALE; NONHUMAN; OBESITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; ROUX Y ANASTOMOSIS; STOMACH BYPASS; TREATMENT RESPONSE;

ANIMALS; DIETARY FATS; EATING; GASTRIC BYPASS; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE TEST; MALE; OBESITY; PEPTIDES; RATS; RATS, LONG-EVANS; RECEPTORS, GLUCAGON; VENOMS; WEIGHT LOSS;

EID: 84893089100     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0511     Document Type: Article

References (28)

1. Kopelman PG. Obesity as a medical problem. Nature 2000;404:635-643
2. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009;9:88
3. Sarwer DB, von Sydow Green A, Vetter ML, Wadden TA. Behavior therapy for obesity: where are we now? Curr Opin Endocrinol Diabetes Obes 2009; 16:347-352
4. Piya MK, Tahrani AA, Barnett AH. Emerging treatment options for type 2 diabetes. Br J Clin Pharmacol. 4 August 2010 [Epub ahead of print]
5. Steinbrook R. Surgery for severe obesity. N Engl J Med 2004;350:1075-1079
6. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg 2013;23:427-436
7. Franco JV, Ruiz PA, Palermo M, Gagner M. A review of studies comparing three laparoscopic procedures in bariatric surgery: sleeve gastrectomy, Roux-en-Y gastric bypass and adjustable gastric banding. Obes Surg 2011;21:1458-1468
8. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122:248-256
9. Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA 2012;308:1122-1131
10. Wickremesekera K, Miller G, Naotunne TD, Knowles G, Stubbs RS. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg 2005;15:474-481
11. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004;89:2608-2615
12. Liu Y, Zhou Y, Wang Y, Geng D, Liu J. Roux-en-Y gastric bypass-induced improvement of glucose tolerance and insulin resistance in type 2 diabetic rats are mediated by glucagon-like peptide-1. Obes Surg 2011;21:1424-1431
13. Woods SC, Seeley RJ, Rushing PA, D'Alessio D, Tso P. A controlled high-fat diet induces an obese syndrome in rats. J Nutr 2003;133: 1081-1087
14. Chambers AP, Stefater MA, Wilson-Perez HE, et al. Similar effects of Roux-en-Y gastric bypass and vertical sleeve gastrectomy on glucose regulation in rats. Physiol Behav 2011;105:120-123
15. Davies MJ, Kela R, Khunti K. Liraglutide-overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab 2011;13:207-220
16. le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006;243:108-114
17. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 1994;93: 2263-2266
18. Brolin RE. Weight gain after short-and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg 2007;246:163-164; author reply 164
19. Shin AC, Zheng H, Townsend RL, Sigalet DL, Berthoud HR. Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery. Endocrinology 2010;151:1588-1597
20. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8:436-447
21. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2011;36:843-854
22. Dushay J, Gao C, Gopalakrishnan GS, et al. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care 2012;35:4-11
23. Koole C, Wootten D, Simms J, et al. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. Mol Pharmacol 2011;80: 486-497
24. Day JW, Li P, Patterson JT, et al. Charge inversion at position 68 of the glucagon and glucagon-like peptide-1 receptors supports selectivity in hormone action. J Pept Sci 2011;17:218-225
25. Kohli R, Kirby M, Setchell KD, et al. Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. Am J Physiol Gastrointest Liver Physiol 2010;299:G652-G660
26. Kindel TL, Yoder SM, Seeley RJ, D'Alessio DA, Tso P. Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. J Gastrointest Surg 2009;13: 1762-1772
27. Wilson-Pérez HE, Chambers AP, Ryan KK, et al. Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide 1 receptor deficiency. Diabetes 2013;62:2380-2385
28. Moberly SP, Mather KJ, Berwick ZC, et al. Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Res Cardiol 2013;108:365